

## **Mechanisms of Heightened Airway Sensitivity and Responses to Inhaled SO<sub>2</sub> in Asthmatics**

Authors: Reno, Anita L., Brooks, Edward G., and Ameredes, Bill T.

Source: Environmental Health Insights, 9(s1)

Published By: SAGE Publishing

URL: <https://doi.org/10.1177/EHI.S15671>

---

BioOne Complete ([complete.BioOne.org](https://complete.BioOne.org)) is a full-text database of 200 subscribed and open-access titles in the biological, ecological, and environmental sciences published by nonprofit societies, associations, museums, institutions, and presses.

Your use of this PDF, the BioOne Complete website, and all posted and associated content indicates your acceptance of BioOne's Terms of Use, available at [www.bioone.org/terms-of-use](https://www.bioone.org/terms-of-use).

Usage of BioOne Complete content is strictly limited to personal, educational, and non - commercial use. Commercial inquiries or rights and permissions requests should be directed to the individual publisher as copyright holder.

---

BioOne sees sustainable scholarly publishing as an inherently collaborative enterprise connecting authors, nonprofit publishers, academic institutions, research libraries, and research funders in the common goal of maximizing access to critical research.

# Mechanisms of Heightened Airway Sensitivity and Responses to Inhaled SO<sub>2</sub> in Asthmatics

Anita L. Reno<sup>1</sup>, Edward G. Brooks<sup>2</sup> and Bill T. Ameredes<sup>1</sup>

<sup>1</sup>University of Texas Medical Branch, Texas, USA. <sup>2</sup>University of Texas Health Science Center at San Antonio, Texas, USA.

## Supplementary Issue: Ambient Air Quality (A)

**ABSTRACT:** Sulfur dioxide (SO<sub>2</sub>) is a problematic inhalable air pollutant in areas of widespread industrialization, not only in the United States but also in countries undergoing rapid industrialization, such as China, and it can be a potential trigger factor for asthma exacerbations. It is known that asthmatics are sensitive to the effects of SO<sub>2</sub>; however, the basis of this enhanced sensitivity remains incompletely understood. A PubMed search was performed over the course of 2014, encompassing the following terms: asthma, airway inflammation, sulfur dioxide, IL-10, mouse studies, and human studies. This search indicated that biomarkers of SO<sub>2</sub> exposure, SO<sub>2</sub> effects on airway epithelial cell function, and animal model data are useful in our understanding of the body's response to SO<sub>2</sub>, as are SO<sub>2</sub>-associated amplification of allergic inflammation, and potential promotion of neurogenic inflammation due to chemical irritant properties. While definitive answers are still being sought, these areas comprise important foci of consideration regarding asthmatic responses to inhaled SO<sub>2</sub>. Furthermore, IL-10 deficiency associated with asthma may be another important factor associated with an inability to resolve inflammation and mitigate oxidative stress resulting from SO<sub>2</sub> inhalation, supporting the idea that asthmatics are predisposed to SO<sub>2</sub> sensitivity, leading to asthma exacerbations and airway dysfunction.

**KEYWORDS:** sulfur dioxide, asthma, IL-10

**SUPPLEMENT:** Ambient Air Quality (A)

**CITATION:** Reno et al. Mechanisms of Heightened Airway Sensitivity and Responses to Inhaled SO<sub>2</sub> in Asthmatics. *Environmental Health Insights* 2015;9(S1) 13–25  
doi: 10.4137/EHI.S15671.

**RECEIVED:** October 06, 2014. **RESUBMITTED:** December 14, 2014. **ACCEPTED FOR PUBLICATION:** December 16, 2014.

**ACADEMIC EDITOR:** Timothy Kelley, Editor in Chief

**TYPE:** Review

**FUNDING:** Support for development of this manuscript was from NIH/NIEHS T32ES007254, NIH/NIEHS 5P30ES006676, The Sealy Center for Environmental Health and Medicine, and the Brown Foundation. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

**COMPETING INTERESTS:** Dr. Edward Brooks has served as a paid expert witness involving the health effects of environmental pollution. Other authors disclose no potential conflicts of interest.

**CORRESPONDENCE:** btamered@utmb.edu

**COPYRIGHT:** © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Published by Libertas Academica. Learn more about this journal.

## Introduction

In 2005, it was estimated that 300 million people worldwide suffered from asthma, with a reported mortality rate of 250,000 people annually.<sup>1</sup> Importantly, by 2025, the number of people affected by this disease is expected to grow by more than 100 million, thus reaching approximately 400 million people worldwide.<sup>1</sup> This prediction projects a 25% increase in the global occurrence of asthma over a 20-year period, a rate that exceeds historical rates of occurrence, even as recently as 20 years ago.<sup>1</sup> As high rates of asthma are typically seen in “Western” industrialized nations, the predicted rise is, in part, predicated on the cultural evolution of less developed cultures and nations toward a western style, with increased industrialization, sanitation, and infectious disease prevention. Associated with this industrial development are numerous sources of gaseous air pollutants, such as sulfur dioxide (SO<sub>2</sub>), ozone (O<sub>3</sub>), and carbon monoxide (CO), which may be associated with increases in asthma prevalence, but are poorly understood with regard to mechanisms of asthma exacerbation.<sup>2–4</sup> Clearly, with the continued industrialization globally, there is some urgency in refining our understanding of the

mechanisms behind asthma associated with inhaled environmental exposure to toxicants.

Asthma is a pulmonary disease characterized by airway inflammation (AI) and reversible airway obstruction that leads to increases in airflow resistance and difficulty in breathing. Previously, asthma was viewed primarily as a disease of airway smooth muscle dysfunction and airway hyper-responsiveness (AHR). While still considered a major component, recent thinking, investigation, and therapeutic approaches over the past 20 years have focused on the significant inflammatory component of this disease that modulates airway function. This has led to an emphasis on trafficking leukocytes and cytokine-associated mechanistic pathways of inflammation within the airways and a focus on increases in eosinophil-associated Th-2 cytokines such as interleukin (IL)-4, IL-5, and IL-13.<sup>5–7</sup> Interestingly, asthmatics are also specifically known to be deficient in the production of IL-10,<sup>8,9</sup> a major anti-inflammatory cytokine, within their airways, which may contribute to their inability to resolve airway inflammation; however, the reason behind this deficiency remains unknown.



Furthermore, recent research has also shown that changes in airway redox conditions through oxidative stress associated with exposure to allergens and environmental toxicants may be a significant factor in the promotion of airway reactivity, and possibly the development and exacerbation of asthma.<sup>10–12</sup> Given that small-molecule gaseous environmental toxicants such as ozone are thought to initiate a local irritative oxidative stress response that can result in direct airway constriction and exacerbation of asthma,<sup>12–14</sup> a similar mechanism may be potentiated by SO<sub>2</sub>; however, there has been a decline in research on inhaled SO<sub>2</sub> in recent years. A PubMed search yielded a relatively small number of inhaled SO<sub>2</sub> articles over the past 5–10 years (average 6–19/year).

Thus, there has been a relative decrease in attention received by SO<sub>2</sub> in recent years. Furthermore, there are additional precedents to consider regarding the activity of the airway cytokine network and irritant/oxidative stress mechanisms that may be potentiated with exposure of asthmatics to a gaseous environmental toxicant, such as sulfur dioxide. A PubMed search encompassing the following terms was performed over the course of 2014: asthma, airway inflammation, sulfur dioxide, IL-10, and mouse and human studies. This search indicated that biomarkers of SO<sub>2</sub> exposure, SO<sub>2</sub> effects on airway epithelial cell function, and animal model data are useful in our understanding of the body's response to SO<sub>2</sub>, which includes oxidative stress that may be treatable with antioxidant therapy. SO<sub>2</sub>-associated amplification of allergic inflammation, as well as promotion of neurogenic inflammation due to chemical irritant properties, may also contribute to those responses.

In this review, we provide information regarding 1) the sources, characteristics, and metabolism of SO<sub>2</sub>, 2) biomarkers of SO<sub>2</sub> exposure, 3) effects of SO<sub>2</sub> *in vitro* and *in vivo*, 4) the generation and scavenging of reactive oxygen/nitrogen species (ROS/RNS) following SO<sub>2</sub> exposure, 5) SO<sub>2</sub> as an environmental toxicant that may be important in the exacerbation of asthma, and 6) the importance of oxidative stress and the cytokine network as factors contributing to the responsiveness of asthmatics to SO<sub>2</sub>, with special reference to the potential role of IL-10. In all cases presented, we have converted the unitary numbers originally published to values in parts per billion (ppb) for ease of comparisons across studies.

## Environmental Sources, Absorption, and Metabolism of SO<sub>2</sub>

**Sources of gaseous SO<sub>2</sub> in the environment.** SO<sub>2</sub> is released as a gas when sulfur-rich fossil fuel is burned (such as coal or diesel), when metal is extracted from ores, and when gasoline is extracted from oil.<sup>15–17</sup> In some industrialized locations, a high probability of SO<sub>2</sub> exposure may be confined to the factory area itself and within the vicinity of several square miles or the original site of its generation.<sup>18,19</sup> Table 1 illustrates average SO<sub>2</sub> concentrations in various cities (“megacities”) across the world. Of the cities represented,

**Table 1.** Annual average SO<sub>2</sub> concentrations during 2000–2005 reported from selected cities worldwide (modified).<sup>20</sup>

REGION	CITY (SELECTED)	ANNUAL AVERAGE SO <sub>2</sub> CONCENTRATIONS IN 2000–2005 (approximations; ppb)
Asia	Beijing	24.8
	Hong Kong	6.9
	Tokyo	3.8
	Mumbai	13.4
	All cities (range)	2.3–24.8
Africa	Harare	38.2
	Cairo	15.3
	Johannesburg	6.9
	Cape Town	3.8
	All cities (range)	3.8–38.2
Latin America	Mexico City	26.7
	Bogota	22.9
	Sao Paulo	15.3
North America	Pittsburgh	13.4
	New York	11.5
	Los Angeles	4.6
	Seattle	3.4
	Vancouver	6.5
Europe	All cities (range)	3.4–13.4
	Athens	11.5
	Berlin	4.6
	Oslo	3.8
	Barcelona	3.8
All cities (range)	3.1–13.7	

Harare (Africa), Mexico City (Latin America), and Beijing (Asia) had the highest concentrations of SO<sub>2</sub> (38.2, 26.7, and 24.8 ppb, respectively).<sup>20</sup> Cairo, Mumbai, Sao Paulo, Athens, and the North American cities of Pittsburgh and New York also represent areas in which industrialization has had an impact in increasing exposures to air pollution, most notably SO<sub>2</sub>.<sup>20</sup> Coal is often used as a primary energy source, which only exacerbates the problem in those cities in which SO<sub>2</sub> levels are already high.<sup>20</sup> A study conducted in Russia by Nieminen et al. (2013) sought to determine whether living in a heavily industrial (mining) area would be a risk factor for respiratory symptoms.<sup>21</sup> They observed that people living closest to areas of high levels of SO<sub>2</sub> had elevated incidences of sputum production and the presence of chronic cough.<sup>21</sup> This study illustrates the relationship between sulfur dioxide levels and industrialization, and gives insight into the importance of setting air quality guidelines.

Due to the commonplace occurrence of industrial processes mentioned above, exposures to SO<sub>2</sub> can be, likewise,



commonplace, which led to adoption of SO<sub>2</sub> exposure standards to protect workers and nearby residents. In 2010, the Environmental Protection Agency (EPA) replaced the existing primary SO<sub>2</sub> standards (annual and 24-hour) with a new 1-hour standard set at a level of 75 ppb (Table 2). The National Institute for Occupational Safety and Health (NIOSH) acceptability standards vary from 5000 ppb (5 ppm) for 15 minutes of SO<sub>2</sub> exposure to 2000 ppb (2 ppm) for 10 hours of exposure (Table 3). Levels of gaseous SO<sub>2</sub> in some polluted urban air are reported as high as 2000 ppb (2 ppm),<sup>18</sup> which can still prove to be problematic for those living with asthma. For example, it is known that the odor detection threshold for humans is approximately 2700 ppb (2.7 ppm), ranging from 330 to 5000 ppb (0.3–5 ppm),<sup>22,23</sup> which means that those suffering from respiratory problems in these industrial areas can live day to day without being aware of their exposure or knowing about the underlying cause of their breathing limitations. Short-term, high-level exposures to SO<sub>2</sub> gas can cause pulmonary edema, while short-term, low-level exposures [as low as 100–500 ppb (0.1–0.5 ppm)] can produce bronchoconstriction in asthmatics.<sup>24–28</sup> However, normal (non-asthmatic) humans exposed to an acute low dose of SO<sub>2</sub> [up to 2000 ppb (2 ppm)] typically do not demonstrate such a response.<sup>29</sup> Most notably, SO<sub>2</sub> has been reported to aggravate airway allergic responses to inhaled allergens,<sup>26,30</sup> signifying that it has properties that can be highly detrimental to atopic asthmatics.

**Absorption of SO<sub>2</sub>: Interaction of SO<sub>2</sub> with airborne particles.** SO<sub>2</sub> is highly water-soluble, forming secondary compounds such as sulfurous (H<sub>2</sub>SO<sub>3</sub>) and sulfuric (H<sub>2</sub>SO<sub>4</sub>) acids, a large portion of which, when inhaled, is readily absorbed/converted within the airway.<sup>31</sup> SO<sub>2</sub> can react with other airborne chemical species, forming secondary particulate matter (PM) [eg, ammonium sulfate (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and gypsum (CaSO<sub>4</sub>·2H<sub>2</sub>O)]<sup>32</sup> over a wide range of particle sizes<sup>33</sup>; the fine and ultrafine particles, rich in the acidic ammonium sulfate, are capable of being carried into the distal airways and alveoli.<sup>17,34</sup> For example, in Houston, Texas, the PM<sub>2.5</sub>

(particulate matter with a diameter of 2.5 μm or less) can be up to 40%–50% sulfur oxide-based.<sup>27</sup> Upon impact with the airways, these sulfur oxide-bearing particulates may theoretically dissolve in the airway lining fluid and produce acidic microenvironments, thereby activating “acid” receptors (transient receptor potential; TRP), calcium channels, and acid-sensing ion channels (ASIC), leading to the activation of inflammatory cascades and possibly damaging cell membranes and inducing oxidative stress responses.<sup>34</sup> Thus, sulfur oxides carried on airborne particulates may be an important source of reactive compounds that are not as easily monitored as compared to the gaseous form of SO<sub>2</sub> itself, and may represent an area requiring a significant amount of further study.

**Metabolism of SO<sub>2</sub> in the body.** Although the respiratory tract is the primary target for SO<sub>2</sub> gas to exert its toxic effects, other organs and systems can also be affected when this gas enters the systemic circulation via the bloodstream.<sup>35</sup> Due to its high water solubility, hydration of SO<sub>2</sub> results in the formation of sulfite (SO<sub>3</sub><sup>2-</sup>) and bisulfite (HSO<sub>3</sub><sup>-</sup>) anions.<sup>35–37</sup> These ions can then be oxidized in the plasma, forming protein S-sulfonates.<sup>35</sup> Gunnison and Palmes (1974) exposed humans to various concentrations of SO<sub>2</sub> [300–6000 ppb (0.3–6 ppm)] for up to 12 hours. They discovered that, as the concentration of SO<sub>2</sub> increased, the level of S-sulfonates also increased.<sup>38</sup> Similar findings have also been described in experimental animal studies.<sup>39</sup> A study conducted by Bechtold et al. (1993) also utilized the presence of S-sulfonate as a potential biomarker of sulfur dioxide exposure. The authors exposed asthmatic subjects to 1000 ppb (1 ppm) SO<sub>2</sub> for 10 minutes and found increased levels of S-sulfonate in the nasal airway lavage fluid (NALF) as compared to air controls.<sup>40</sup> These studies indicate that protein S-sulfonates have the potential to be good indicators of SO<sub>2</sub> exposure. As of yet, no studies have correlated degrees of elevated S-sulfonates with altered respiratory function measurements [eg, forced expiratory volumes after 1 second (FEV<sub>1</sub>)], so this needs to be explored.

Studies in sulfite oxidase-deficient animals have proven to be key in deciphering the role that sulfites play in organ toxicity, as well as indicating how cellular defense mechanisms can become overwhelmed. For example, Izgut-Uysal et al. (2005) showed that the phagocytic and chemotactic functions of peritoneal macrophages of normal rats were

**Table 2.** Evolution of SO<sub>2</sub> primary National Ambient Air Quality Standards (modified).<sup>137</sup>

YEAR	AVERAGING TIME	LEVEL
1971	24-hr	140 ppb
	Annual	30 ppb
1996	(Existing 1971 standards retained)	
2010	1-hr	75 ppb
	24-hr	(revoked)
	Annual	(revoked)

**Notes:** Averaging time is defined as the “time period established for specific national ambient air quality standards, which must be used when interpreting air quality data.” The 1971 standards were revoked in 2010 because they “would not provide additional public health protection given a 1-hour standard at 75 ppb.” The SO<sub>2</sub> regulatory standard is the 99th percentile of 1-hour daily maximum concentrations, averaged over 3 years.

**Table 3.** Comparison of primary National Ambient Air Quality Standards for SO<sub>2</sub>, odor detection, and health effects.

STANDARD	EPA	NIOSH
15 min	–	5000 ppb
1 hr	75 ppb	–
10 hr	–	2000 ppb

**Notes:** Odor detection threshold: 330–5000 ppb (2700 ppb avg). Health effects: non-asthmatic (>2000 ppb); asthmatic (≥400–500 ppb).



increased following exposure to sulfite, but were even further enhanced in macrophages from the sulfite oxidase-deficient rats. In 1987, Gunnison et al. observed higher concentrations of sulfite in rats lacking sulfite oxidase compared to those animals competent in the enzyme, which did not bioaccumulate sulfite in their plasma following SO<sub>2</sub> exposure. Given that asthmatics are known to be highly sensitive to SO<sub>2</sub> and, therefore possibly, sulfite, one could speculate that they might have a relative deficiency in the sulfite oxidase detoxification enzyme,<sup>41</sup> but this has yet to be studied. In considering its elimination mechanism from the body, the excretion fate of SO<sub>2</sub> is associated with its cellular metabolism within the mitochondria, as the mitochondrial enzyme sulfite oxidase detoxifies bisulfite, which is typically excreted in the urine as inorganic sulfate.<sup>35,36</sup>

### SO<sub>2</sub> Actions in Asthma: (some of) What is Known

**Biomarkers of SO<sub>2</sub> exposure.** Recent emphasis has been placed on the assessment of biomarkers in the determination of disease, drug, and toxicity effects.<sup>42</sup> Interestingly, some asthmatic patients carry a genetic polymorphism linked to the bronchial hyper-responsiveness that is triggered by exposure to SO<sub>2</sub>.<sup>43</sup> For example, the study by Winterton et al. (2001) sought to determine which genetic polymorphism might be responsible for this reaction, and they found that 13 of 62 asthmatic subjects screened had decreased FEV<sub>1</sub> of 12% or greater, as compared to baseline, following inhalation of 500 ppb (0.5 ppm) SO<sub>2</sub> for 10 minutes.<sup>43</sup> This SO<sub>2</sub>-induced bronchoconstriction was linked to a polymorphism at position -308 on the tumor necrosis factor (TNF)- $\alpha$  gene promoter [100% (12 of 12) of SO<sub>2</sub> responders versus only 61% (28 of 68) of SO<sub>2</sub> nonresponders], with no additional polymorphisms observed to be involved.<sup>43</sup> At the level of protein production, a protein biomarker study conducted by Liu et al (2009) focused on breath condensate from asthmatic children following SO<sub>2</sub> exposure [3-day average of 5.4 ppb (0.0054 ppm)], in which thiobarbituric acid reactive substances (TBARS) analysis indicated an increase in oxidative stress within their airways. Pulmonary function in those children was reported to decrease after SO<sub>2</sub> exposure, as well,<sup>11</sup> suggesting a significant relationship between SO<sub>2</sub>-associated oxidative stress and pulmonary dysfunction. These data suggest that both genetic and protein biomarkers can be used to help monitor and evaluate human exposure to SO<sub>2</sub> (Table 4), which may be of use in future assessments of SO<sub>2</sub> toxicity and, possibly, mechanisms of asthma.

Besides evaluating exhaled breath condensate (EBC) and pulmonary function, other noninvasive techniques have been used to evaluate the extent of SO<sub>2</sub> effects on the lung, following exposure to SO<sub>2</sub>.<sup>29</sup> For example, Raulf-Heimsoth et al. (2009) collected NALF samples from healthy non-asthmatic study volunteers exposed to 0–2000 ppb (0–2 ppm) SO<sub>2</sub> for four hours with two moderate exercise intervals. This acute exposure did not induce alterations in exhaled nitric oxide (F<sub>E</sub>NO,

which can be typically associated with eosinophilic airway inflammation), nor did it induce alterations in biomarkers typically measured within the EBC [leukotriene B<sub>4</sub> (LTB<sub>4</sub>), prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), 8-isoprostane (8-isoPGF<sub>2 $\alpha$</sub> )] or NALF [Substance P, IL-8, brain-derived neurotrophic factor (BDNF)].<sup>29</sup> Although no significant differences were seen for NO-associated biomarkers tested in the healthy subjects, it is reasonable to postulate that changes in NO-associated biomarkers might be responsible with an increase in airway irritation and inflammation in asthmatic subjects inhaling SO<sub>2</sub>, given that exhaled NO has been shown to be elevated in asthmatic patients.<sup>44</sup> While evidence for this potential association remains scant at this time, measures of NO and other EBC components are becoming more routinely available and could provide a wealth of relatively easily obtainable information regarding the effects of SO<sub>2</sub> in both asthmatics and non-asthmatics in future studies of both exposure and therapeutic modulation of its effects.

Biomarkers of systemic inflammation also have been evaluated in plasma collected from SO<sub>2</sub>-exposed subjects.<sup>14,45–48</sup> An ambient air pollution exposure study in humans revealed a positive correlation between IL-6 and SO<sub>2</sub>.<sup>14</sup> However, fibrinogen and SO<sub>2</sub> were not correlated,<sup>14</sup> even though exposure to high levels of concentrated ambient air particles has been shown to be significantly associated with elevated fibrinogen levels, presumably due to pollutant-associated tissue damage.<sup>46</sup> Two additional studies sought to determine a link between chronic exposure to outdoor air pollutants and the inflammatory biomarkers fibrinogen and C-reactive protein (CRP). Forbes et al. (2009) concluded that concentrations of fibrinogen and CRP were not associated with all four chronic air pollution measurements (PM<sub>10</sub>, NO<sub>2</sub>, SO<sub>2</sub>, and O<sub>3</sub>); fibrinogen was actually negatively associated. On the other hand, a study conducted by Hoffmann et al., published in the same year (2009), concluded that, at least for men, chronic exposure to particulate matter air pollution was highly correlated with levels of CRP. Similarly, a 3-year study of Japanese children<sup>48</sup> chronically exposed to air pollution [encompassing suspended particulate matter, nitrogen dioxide (NO<sub>2</sub>), and SO<sub>2</sub>] also reported elevated levels of fibrinogen. This marked variability needs to be further evaluated to assess the effects of gaseous SO<sub>2</sub> on fibrinogen, but suggests that there may be some potentially important association between SO<sub>2</sub> complexed onto particulates, CRP, and fibrinogen, such that CRP and fibrinogen may be measurable biomarkers of SO<sub>2</sub> exposure. These biomarkers would presumably be easily measurable in a simple blood sample, which could be routinely obtained and analyzed with minimal difficulty.

The biomarker studies mentioned above suggest a preliminary and, most importantly, noninvasive way to identify and characterize SO<sub>2</sub>-induced lung dysfunction and/or injury, and confirm potential pathways that might be targeted and modified with anti-inflammatory therapy. It is evident that 1) genetics may play an important role in one's susceptibility to the

**Table 4.** Pollution-associated biomarkers.

SAMPLE ANALYSIS	STUDY POPULATION	POLLUTANT(S) AND LEVEL OF EXPOSURE	OBSERVATIONS	REFERENCES
Exhaled breath condensate (EBC)	Asthmatic children, ages 9–14	5.4 ppb SO <sub>2</sub> , 6.8 ppb NO <sub>2</sub> , and 5.4 µg/m <sup>3</sup> PM <sub>2.5</sub> ; 3-day average during 4-week study	TBARS indicated ↑ in oxidative stress and ↓ in FEV <sub>1</sub>	[11]
	Healthy non-asthmatics, ages 19–36	0–2000 ppb SO <sub>2</sub> ; 4-hr exposure	No change in FeNO, LTB <sub>4</sub> , PGE <sub>2</sub> , 8-isoPGF <sub>2α</sub>	[29]
Nasal lavage fluid (NALF)	Healthy non-asthmatics, ages 19–36	0–2000 ppb SO <sub>2</sub> ; 4-hr exposure	No change in Substance P, IL-8, BDNF	[29]
Plasma	Non-asthmatic and asthmatic adults, ages 19–48	0–70 ppb SO <sub>2</sub> ; 2–3-yr study	Positive correlation between SO <sub>2</sub> and IL-6, but not between SO <sub>2</sub> and fibrinogen	[14]
	Non-asthmatics, ages 18–40	8.8–119 ppb concentrated ambient air particles: 2-hr exposure	Air pollution is associated with elevated fibrinogen	[46]
	Non-asthmatics, ages 16–75+	19.5, 17.9, and 16.2 µg/m <sup>3</sup> PM <sub>10</sub> ; 10.2, 13.5, and 8.6 ppb NO <sub>2</sub> ; 3.6, 2.3, and 1.6 ppb SO <sub>2</sub> ; 20.4, 19.4, 21.4 ppb O <sub>3</sub> ; medians for years 1994, 1998, and 2003	Fibrinogen and CRP are not associated with air pollutants, fibrinogen negatively associated	[45]
	Non-asthmatics, ages 45–75	37.7 µg/m <sup>3</sup> PM <sub>2.5</sub> ; mean for Dec 2000–July 2003	For men, PM <sub>2.5</sub> exposure is highly correlated with CRP and fibrinogen	[47]
	Non-asthmatic and asthmatic children, and children with wheeze, ages 6–12	26.7–42.7 µg/m <sup>3</sup> suspended particulate matter: 11.7–29.0 ppb NO <sub>2</sub> ; 4.3–6.3 ppb SO <sub>2</sub> ; 3-yr study	For children with wheeze, air pollution exposure is correlated with CRP	[48]

**Abbreviations:** TNF- $\alpha$ , tumor necrosis factor-alpha; FEV<sub>1</sub>, forced expiratory volume after 1 second; TBARS, thiobarbituric acid reactive substances; F<sub>e</sub>NO, fractional exhaled nitric oxide; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; PGE<sub>2</sub>, prostaglandin E<sub>2</sub>; 8-isoPGF<sub>2 $\alpha$</sub> , 8-isoprostane; IL-8, interleukin-8; BDNF, brain-derived neurotrophic factor; IL-6, interleukin-6; CRP, C-reactive protein.

effects of SO<sub>2</sub> in relation to asthma, and 2) this susceptibility may be decipherable using controlled SO<sub>2</sub> exposure studies. Furthermore, as mentioned above, many people, including asthmatics, could be exposed to SO<sub>2</sub> at insensible levels, the results of which, either early or over time, may ultimately be identified with the measurement of biomarkers, such as those discussed above. While further study is needed to more comprehensively assess the relationship of measurable biomarkers with adverse symptoms in asthmatics, the evidence above suggests that biomarkers may ultimately assist in the understanding of the mechanism behind the effects of SO<sub>2</sub> in asthmatics and its possible treatment.

**Epithelial cell studies: Effect of SO<sub>2</sub> and derivatives on gene and protein expression.** The effects of SO<sub>2</sub> and its derivatives on various asthma-related genes in human bronchial epithelial cells have been studied in order to determine the possible molecular mechanisms of asthma in relation to the fact that airway epithelial cells are the initial cell barrier, or airway contact point, of inhaled SO<sub>2</sub> gas and sulfates on inhaled particulates (Table 5).<sup>49–52</sup> Two studies, published in 2007, utilized the human papilloma virus (HPV)-18 immortalized human bronchial epithelial cell line BEP2D and examined the effects of SO<sub>2</sub> on mRNA and protein expression of epidermal growth factor (EGF), epidermal growth factor receptor (EGFR), intercellular adhesion molecule (ICAM)-1, cyclooxygenase (COX)-2, mucin-5 subtype AC (MUC5AC), and IL-13.<sup>49,50</sup> EGF and its receptor EGFR have been associated

with the repair of inflammatory events and production of mucin.<sup>50,53,54</sup> In contrast, ICAM-1 has been found to promote inflammation and hyper-responsiveness in asthma.<sup>50,55</sup> Because COX-2 controls prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) synthesis and, additionally, because increased levels of PGD<sub>2</sub> are thought to cause the constriction of airway smooth muscle, it is conceivable that PGD<sub>2</sub>-induced narrowing of bronchi and the encouragement of recruitment and endurance of inflammatory cells<sup>50,56,57</sup> could be a mechanism through which SO<sub>2</sub> exerts its effects within the airway. In support of this idea, mRNA and protein levels of EGF, EGFR, ICAM-1, COX-2, MUC5AC, and IL-13 were found to be elevated in BEP2D cells treated with SO<sub>2</sub> derivatives [sodium bisulfite (NaHSO<sub>3</sub>) and sodium sulfite (Na<sub>2</sub>SO<sub>3</sub>); 0.0001, 0.001, 0.01, 0.1, and 1 mM], indicating that those asthma-related genes modulate inflammation in the airways and promote hyper-secretion of mucus following SO<sub>2</sub> exposure.<sup>49,50</sup>

Prior to beginning their human epithelial lung cell study, Pelletier et al. (2002) noted that it had not yet been proven that this cell type could be activated by sodium sulfite. The authors subsequently demonstrated such activation by incubating the epithelial cell line A549 with increasing concentrations of sodium sulfite (0.01–10 mM), which resulted in generalized protein tyrosine phosphorylation events and IL-8 production.<sup>51</sup> They also observed adhesion of neutrophils to the sodium sulfite-activated epithelial lung cells following sodium sulfite exposure, which was shown to be independent

**Table 5.** Epithelial cell studies with SO<sub>2</sub>.

CELL TYPE	OBSERVATIONS	REFERENCES
HPV-18 immortalized human bronchial epithelial cells (BEP2D)	Sodium bisulfite and sodium sulfite-exposed cells (0.0001, 0.001, 0.01, 0.1, and 1 mM; 4-hr exposure) displayed increased transcription and translation of EGF, EGFR, ICAM-1, COX-2, MUC5AC, and IL-13.	[49],[50]
A549	Sodium sulfite-exposed cells (0.01–10 mM; 24-hr exposure) showed initiation of phosphorylation events on the Tyr residue, IL-8 production, and neutrophil adhesion.	[51]
	1. NFκB, ERK1/2, and p38 play an important role in IL-8 gene expression following sodium sulfite exposure (0, 100, 500, 1000, and 2500 μM; 16-hr exposure). 2. Treatment with fluticasone, salmeterol, and montelukast decreased the production of IL-8.	[52]

**Abbreviations:** EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ICAM-1, intercellular adhesion molecule 1; COX-2, cyclooxygenase-2; MUC5AC, mucin-5 subtype AC; IL-13, interleukin-13; Tyr, tyrosine; NFκB, nuclear factor kappa B; ERK1/2, extracellular signal-regulated kinases 1 and 2.

of intercellular or vascular adhesion molecules ICAM-1/-3, or vascular cell adhesion molecule (VCAM)-1, respectively.<sup>51</sup> Moreover, a study conducted by Yang et al. in 2008 evaluated the effects of various asthma-controlling drugs on sodium sulfite-induced inflammation (0, 100, 500, 1000, 2500 μM) in A549 cells. They found that nuclear factor kappa B (NF-κB), extracellular signal-regulated kinases 1 and 2 (ERK1/2), and p38 all play an integral role in the gene expression of IL-8 after sodium sulfite exposure.<sup>52</sup> Their results further showed a decrease in sodium sulfite-induced IL-8 production following treatment with fluticasone, salmeterol, and montelukast,<sup>52</sup> each of which is known to have differing mechanisms of action (steroid, β-agonist, and leukotriene modifier, respectively). Thus, the studies above strongly indicate that there is significant evidence for the effects of SO<sub>2</sub> on epithelial cell activation.

**SO<sub>2</sub> studies in animal models: Guinea pigs.** A number of animal studies, notably those of guinea pigs, have investigated the effects of SO<sub>2</sub> on the airways (Table 6).<sup>58,59</sup> Studies in guinea pigs may be particularly instructive and translational in this case because of the relatively enhanced nasal and lower airway sensitivity of that species and its similarity to humans regarding histamine-driven immunoglobulin (Ig)E responses.<sup>60–62</sup> For example, one study in guinea pigs found that inhalation of SO<sub>2</sub> [200,000–300,000 ppb (200–300 ppm) for 4 h/day over 4 days] induced AI and enhanced sensitivity to histamine, which were associated with elevations in ROS.<sup>58</sup> Another study in guinea pigs showed an enhancement in the development of allergen-induced asthma following repeated exposures to low levels of SO<sub>2</sub> [100 ppb (0.1 ppm) for 5 h/day over 5 days].<sup>59</sup> In that study, SO<sub>2</sub>-exposed animals had increased enhanced pause (Penh; a measure of airway obstruction, *in vivo*), increased bronchoalveolar lavage fluid (BALF) eosinophil counts and inflammatory cell infiltration into the lung parenchyma, as well as damage to the bronchiolar epithelium.<sup>59</sup> Here, evidence from guinea pig models has shown that SO<sub>2</sub> inhalation plays a role in exacerbating AI, whereby ROS levels are modulated and associated changes in airway leukocyte infiltrates abound.

**SO<sub>2</sub> studies in animal models: Mice.** Although mice typically do not have exactly the same sensitivities and

driving mechanisms as guinea pigs, they do express aspects of airway inflammation and airway hyper-responsiveness that make them useful models for some comprehensive studies (Table 6).<sup>63–67</sup> For example, inhalation of SO<sub>2</sub> [8400–42,700 ppb (8.4–42.7 ppm)] over a week (6 h/day over 7 days) resulted in lipid peroxidation and a decrease in lung antioxidant levels in mice.<sup>65</sup> A later study by the same group indicated that, as a result of SO<sub>2</sub> inhalation, the sulfite content in the lungs of mice was higher than that in the heart or brain, which might be explained by the fact that the lung is exposed to SO<sub>2</sub> first (as a first-pass organ).<sup>66</sup> An alternative explanation for those data could also be that the enzymatic action of sulfite oxidase is more efficient in the heart, brain, liver, and kidney, as compared to the lung<sup>17,66,68–70</sup>; this will take further study to resolve. Furthermore, measurement of cytokine levels in the lungs of those SO<sub>2</sub>-exposed mice also showed a significant skewing of the pro-inflammatory/anti-inflammatory balance toward pro-inflammatory.<sup>67</sup> In contrast to some mice, eg, C57Bl6 and C3 strains that are mild responders,<sup>71</sup> a fairly recent key study in BALB/c mice (typically considered strong AI responders) investigated the effect of acute induction of AI by a combination of inhaled SO<sub>2</sub> [50,000 ppb (50 ppm) for 1 h/day over 3 days] followed by inhalation of ovalbumin, which resulted in a subsequent induction of chronic allergic AI.<sup>63</sup> Importantly, this acute SO<sub>2</sub> exposure model, accompanied by an allergen trigger, exemplified that the exposure to SO<sub>2</sub> promoted a significant enhancement in the AI response.<sup>63</sup> A similar finding was reported in another BALB/c model utilizing a combination of SO<sub>2</sub> inhalation exposure and house dust mite allergen.<sup>64</sup> Thus, evidence from mouse models has shown that allergic AI is highly exacerbated by SO<sub>2</sub> inhalation, and is coupled with changes in ROS levels, pro-inflammatory versus anti-inflammatory balance, and antioxidant responses.

**SO<sub>2</sub> studies in animal models: Rats.** Lungs and airways of rats have also been studied to elucidate the effects of SO<sub>2</sub> on gene expression related to asthma and apoptosis, as well as xenobiotic-metabolizing cytochrome P450s (Table 6).<sup>72–77</sup> For example, studies by Li et al. measured mRNA and protein levels of MUC5AC, ICAM-1, EGF, EGFR, and COX-2 in

**Table 6.** SO<sub>2</sub> experiments in animal models.

ANIMAL MODEL	STRAIN	OBSERVATIONS	REFERENCES
Guinea Pig	Hartley, Dunkin- Hartley	SO <sub>2</sub> (200–300 ppm; 4 hr/day/4 days) induced AI and enhanced sensitivity to histamine due to elevations in ROS	[58]
		SO <sub>2</sub> inhalation (0,1 ppm; 5 hr/day/5 days) increased Penh, BALF eosinophil counts, and infiltration of inflammatory cells; damaged epithelium	[59]
Mouse	Kungming albino	SO <sub>2</sub> inhalation (8.4, 21.4, and 42.7 ppm; 6 hr/day/7 days) induced lipid peroxidation and decreased anti-oxidant levels	[65]
	BALB/c	SO <sub>2</sub> inhalation (5.3, 10.7, and 21.4 ppm; 4 hr/day/7 days) [lower sulfite oxidase levels?]; cytokine levels showed a shift toward pro-inflammatory	[66],[67]
Rat	Wistar	Exposure to SO <sub>2</sub> (50 ppm; 1 hr/day/days 7, 9, 11) or sodium sulfite (5 mM; days 1–22) promotes an enhancement in the AI response	[63],[64]
		OVA compounded with SO <sub>2</sub> (2 ppm; 1 hr/day/days 15–21) enhanced mRNA and protein levels of EGF, EGFR, COX-2, MUC5AC, and ICAM-1 to a greater degree than allergen alone	[73],[74]
		SO <sub>2</sub> exposure (2.7, 5.3, and 10.7 ppm; 6 hr/day/7 days) increased levels of TNF- $\alpha$ , IL-1 $\beta$ , ICAM-1, and iNOS mRNA	[77]
		SO <sub>2</sub> challenge (2 ppm; 1 hr/day/days 15–21) inhibited expression of p53 and bax, while the expression of bcl-2 was promoted	[76]
		SO <sub>2</sub> exposure (5.3, 10.7, and 21.4 ppm; 6 hr/day/7 days) increased bax mRNA levels, while levels of bcl-2 remained unchanged	[72],[77]
		SO <sub>2</sub> inhalation (5.3, 10.7, and 21.4 ppm; 6 hr/day/7 days) suppressed the expression of CYP1A1 and CYP1A2	[75]

**Abbreviations:** Penh, enhanced pause; IL-1 $\beta$ , interleukin-1 $\beta$ ; iNOS, inducible nitric oxide synthase.

allergen (OVA)-exposed, SO<sub>2</sub>-exposed, and OVA + SO<sub>2</sub>-exposed male Wistar rats. Compared to control rats, OVA alone significantly increased mRNA and protein levels of these asthma-related genes, while OVA co-exposed to SO<sub>2</sub> [2000 ppb (2 ppm) for 1 h/day over 7 days] enhanced the mRNA and protein levels of MUC5AC, ICAM-1, EGF, EGFR, and COX-2 to a greater degree than the allergen inhalation by itself.<sup>73,74</sup> These results further developed and confirmed the *in vitro* data mentioned previously in the epithelial cell studies section. Yun et al. (2011) observed increased levels of TNF- $\alpha$ , IL-1 $\beta$ , ICAM-1, and inducible nitric oxide synthase (iNOS) mRNA in their male Wistar rat model of SO<sub>2</sub> exposure [2700–10,700 ppb (2.7–10.7 ppm) for 6 h/day over 7 days]. Another study using the same strain of rats showed that the expressions of pro-apoptotic genes (p53 and bax) were inhibited by SO<sub>2</sub> challenge [2000 ppb (2 ppm) for 1 h/day over 7 days], while the expression of an anti-apoptotic gene (bcl-2) was promoted.<sup>76</sup> On the other hand, two independent SO<sub>2</sub> exposure studies [encompassing the range 2500–20,000 ppb (2.5–20 ppm) for 6 h/day over 7 days] in male Wistar rats illustrated increases in bax mRNA levels in the lung, while bcl-2 mRNA levels remained the same.<sup>72,77</sup> The reason for the discrepancy in the two studies could be related to the concentration of SO<sub>2</sub> used, or perhaps due to the fine balancing that occurs between pro- and anti-apoptotic genes, in a diseased lung versus a nondiseased lung.<sup>78</sup> Finally, Qin and Meng (2005) observed suppression of cytochrome

P450 (CYP)1A1 and CYP1A2 expression in the lungs of rats following SO<sub>2</sub> exposure [5300–21,000 ppb (5.3–21 ppm) for 6 h/day over 7 days], suggesting a potential metabolic or oxidant effect. Taken together, these gene expression data might be indicative of a possible mechanism by which SO<sub>2</sub> encourages and maintains an inflammatory status in the asthmatic lung, while the cytochrome P450 data might indicate a mechanism whereby SO<sub>2</sub> may trigger protective responses within the normal lung.

#### Generation of ROS/RNS associated with SO<sub>2</sub> exposure.

Asthma is an inflammatory disease known to be associated with the generation of ROS as a consequence of ROS-producing leukocytes, most notably eosinophils, neutrophils, and macrophages, recruited to the sites of inflammation and/or injury in the airways.<sup>79</sup> Airway leukocytes also release a wide range of enzymes involved in inflammation. One enzyme implicated in the formation of ROS in the asthmatic lung following SO<sub>2</sub> exposure is nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.<sup>80</sup> Although not necessarily translatable to *in vivo* responses, studies of specific mechanisms within cell culture models can be instructive toward our understanding of the effects of SO<sub>2</sub> in the lung. For example, a study conducted by Beck-Speier et al. (1993) examined the effects of low concentrations of sulfite (0.01–1 mM) on human neutrophils, *in vitro*, and found that NADPH oxidase activity was significantly increased when compared to control cells not exposed to sulfite. Neutrophils are known to have an inherently decreased





activity of sulfite oxidase, leaving them vulnerable to the effects of sulfite,<sup>68</sup> which may, in turn, be responsible for the elevations in NADPH oxidase activity observed with sulfite exposure. In human alveolar macrophages and peripheral blood mononuclear cells exposed to 300–1500 ppb (0.3–1.5 ppm) SO<sub>2</sub> for 30 or 120 minutes concluded that vast amounts of ROS were produced following activation of these cell types by SO<sub>2</sub>.<sup>81</sup> It has also been shown that superoxide production can be triggered by sodium sulfite on its own,<sup>82</sup> and that increases in levels of NADPH oxidase can be circumvented by the addition of superoxide dismutase (SOD), a potent antioxidant.<sup>80</sup> In support of that idea, a study utilizing rat basophilic leukemia cells pretreated with diphenyleioidinium (DPI; an inhibitor of NADPH oxidase) showed a 50% inhibition of sulfite-induced ROS formation,<sup>83</sup> again demonstrating the strong relationship between sulfite exposure and ROS formation. Thus, cellular NADPH oxidase has been implicated as a crucial enzyme responsible for the oxidative responses upon challenge with sulfite,<sup>83</sup> and may have important ramifications for the effects of SO<sub>2</sub> and particulate-borne sulfites in the asthmatic lung.

Oxidative stress brought on by various cellular insults, or polymorphisms in oxidative stress genes, can promote the generation of free oxygen radicals, most notably superoxide.<sup>84</sup> Superoxide can then complex with and oxidize NO, thus creating the highly reactive species peroxynitrite, which can, in turn, initiate lipid peroxidation in the cell. Empirically, NO protects the cell from the detrimental effects of ROS, but loses this beneficial effect once oxidized by superoxide.<sup>85</sup> Furthermore, activation of NF-κB is regulated by NO, and this activation can be used as a direct indication of NO bioavailability in an oxidant-stress-laden environment.<sup>85</sup> Thus, in the oxidative setting of the asthmatic lung, high levels of NO encourage the development of RNS, which oxidize cellular components, most notably proteins, and create an overwhelming chronic inflammatory status.<sup>86</sup>

**ROS/RNS scavenging: A treatment for SO<sub>2</sub> exposure in asthma?** Environmental pollutant triggers such as SO<sub>2</sub> are known to promote oxidative stress and AI in asthmatics<sup>11</sup> and in animal models.<sup>87</sup> An important process in the resolution of airway inflammation is the removal of ROS from the cellular environment.<sup>80,85,88–90</sup> Numerous antioxidants, such as glutathione (GSH), heme oxygenase-1 (HO-1), and SOD, have been implicated, and are capable of carrying out this task.<sup>80,90</sup>

Extracellular superoxide dismutase (EC-SOD) is the most abundant SOD in the body, which is highly expressed in mammalian lungs,<sup>88</sup> and may significantly contribute to neutralization of ROS. Ahmed et al. (2011) transfected C10 mouse lung epithelial cells (known to be significant sources of pro-inflammatory cytokines) with human EC-SOD, and observed that NO bioavailability was conserved, which prevented activation of NF-κB, normally a result of oxidative stress. In this case, EC-SOD protected the cells from the detrimental effects of NF-κB activation (via scavenging of superoxide free radical), which is the downstream induction of pro-inflammatory cytokines and mediators. This implies that

pulmonary diseases characterized by oxidative stress, such as asthma, compounded with SO<sub>2</sub> inhalation, might be alleviated by the administration of EC-SOD<sup>88,89</sup>; however, this requires further investigation, in the context of SO<sub>2</sub> exposure.

In support of the idea that oxidative status is important in asthma, deficiencies of plasma levels of dietary antioxidants, such as vitamins C (ascorbic acid), E (α-tocopherol), and D, have been associated with lung disease.<sup>91–100</sup> In 1996, Redlich et al. noted the feasibility of using serum and BAL cell levels of vitamin E to predict lung levels of vitamin E. With this knowledge, Trenga et al. (1999) conducted a study that illustrated reductions in plasma vitamin C and E concentrations in asthmatic adults exposed acutely to SO<sub>2</sub> [500 ppb (0.5 ppm for 10 minutes)] and moderate exercise. Those investigators extended the results by supplementing the diets of adult asthmatics exposed to SO<sub>2</sub> with a combined regimen of vitamins C and E, and revealed a marked attenuation of bronchial hyper-responsiveness when compared to those study subjects given a placebo.<sup>99</sup> Likewise, increases in FEV<sub>1</sub> were noted in exercise-induced asthma (EIA) after vitamin C supplementation.<sup>92,96,97</sup> Furthermore, a study by Fogarty et al. (2006) described how a diet supplemented with vitamin C was associated with reduced use of corticosteroids in asthmatics.

Recently, the beneficial effects of vitamin D have also received significant attention.<sup>91,94,100</sup> Over the course of 4 years, the Childhood Asthma Management Program (CAMP) trial sought to determine the relationship, if any, between asthma severity and serum vitamin D levels.<sup>91</sup> This study, and others, have indicated that vitamin D insufficiency is linked to an increased risk for bronchial hyper-responsiveness and lowered lung function (asthma exacerbations), and increased exacerbations requiring emergent care.<sup>91,94,100</sup> However, more recently, Castro and colleagues (2014) have reported that vitamin D supplementation in adults with persistent asthma and vitamin D deficiency did not alter first treatment failure rate or asthma exacerbations.<sup>101</sup> These seemingly divergent findings suggest an age-related difference in the effect of vitamin D supplementation on asthma in the child and adult populations, which needs to be further investigated. Even so, given the implications of dietary antioxidants in lung disease, it is reasonable to consider the use of antioxidants in asthmatics whose asthma may be exacerbated with environmental SO<sub>2</sub> exposure, in which reactive oxidants may play a significant role.

**Potential for an SO<sub>2</sub>-associated neurogenic inflammatory mechanism.** As outlined above, oxidative stress associated with ROS generation may be important in promoting the inflammatory and physiological effects of inhaled SO<sub>2</sub> and inhaled particulate-borne sulfates within the airway. One possible mechanism through which ROS may act to produce exacerbations in asthmatics is through the inherent “irritant” properties of SO<sub>2</sub> and subsequent induction of neurogenic inflammation. Neurogenic inflammation is defined as inflammation stemming from the nervous system following stimulation of chemical irritant receptors on sensory nerves.<sup>102</sup>



Activation of TRPA1, TRPV1, and ASICs in response to SO<sub>2</sub> and/or secondary acid formation have been associated with the activation of airway inflammation and cough in animal models.<sup>103,104</sup> Neuropeptide mediators such as calcitonin gene related peptide (CGRP), Substance P, and neurokinin A are released from sensory nerves and stimulate effector cells to initiate an inflammatory response.<sup>102,105</sup> Furthermore, neuropeptide release resulting from neurogenic inflammation can mimic the pathology of asthma that is seen in the case of immune-system-induced inflammation<sup>102</sup>; however, these inflammatory responses have been found to be distinct from the typical allergen-induced inflammation regulated by the immune system, suggesting the expression of different asthma phenotypes due to distinct stimuli and mechanistic pathways.<sup>106</sup>

In the presence of a moist environment, such as in the nasal passages and airways, SO<sub>2</sub> converts into sulfuric acid, which can activate chemical irritant receptors and potentially set into motion subsequent non-allergic-associated neurogenic inflammatory responses.<sup>107</sup> Airway acidification is a strong inducer of bronchospasm, and low EBC pH has been associated with acute exacerbations of asthma<sup>108</sup> and poor asthma control.<sup>109,110</sup> The role of chemical irritants, such as SO<sub>2</sub>, and their association with neurogenic inflammation have been studied in animal models of asthma.<sup>102,111–113</sup> For example, formaldehyde, a chemical widely present in the environment in household products, cigarette smoke, and industrial exhaust,<sup>114–116</sup> was found to promote a neurogenic inflammatory response that was separate from an allergic immunological response in a mouse model of inflammation.<sup>112</sup> Plasma levels of Substance P were significantly increased in animals exposed to inhaled formaldehyde at the level of 2000 ppb (2 ppm), providing strong evidence for stimulation of pulmonary C-fibers resulting in a non-allergen-associated inflammatory response induced by the nervous system.<sup>112</sup> Similarly, a study of airway injury with low-level inhaled SO<sub>2</sub> [400 ppb (0.4 ppm) for 6 h/day over 3 days] in rats implicated neurogenic inflammation as a “critical pathophysiological mechanism” due to the observations of significantly elevated levels of Substance P in plasma and positive staining for Substance P in C-fibers within the lung tissue.<sup>113</sup> Given that the study by Lin et al. (2009) was the only research article found after searching for the terms “SO<sub>2</sub> and neurogenic inflammation” illustrates the need to possibly shift our thinking toward the potential that the nervous system may play a significant role in the inflammatory response associated with SO<sub>2</sub> inhalation and exacerbations of asthma.


## Gaps in SO<sub>2</sub> Knowledge and Research

**Potential for an IL-10-deficiency-associated mechanism of SO<sub>2</sub> sensitivity in asthma.** The studies and evidence outlined above point to some suggestions as to how SO<sub>2</sub> and particulate-borne sulfates may exert their effects on the airway; however, the question remains as to why asthmatics seem to be highly responsive to SO<sub>2</sub>. As shown in Figure 1, it is

clear that oxidative stress is an important driver of AI, and that SO<sub>2</sub> promotes ROS production in the lung which can drive AI, possibly through either classical allergen-associated mechanisms or neurogenic mechanisms. While antioxidants may afford some protection from ROS-induced oxidative stress, it is also well established that anti-inflammatory drug treatments, such as corticosteroid administration, substantially reduce AI. This resolution of inflammation, or its suppression in the case of inhaled corticosteroids given as regularly scheduled asthma-controller medication, includes reduced trafficking of leukocytes, particularly eosinophils, as well as reduced pro-inflammatory cytokine and chemokine production.<sup>117–119</sup> These effects may occur, in part, through increases in IL-10 associated with steroid treatment.<sup>117–119</sup> However, the role of IL-10 in the airway response to SO<sub>2</sub> has been essentially unstudied. Considering that the production of IL-10 is deficient in the lungs of people with asthma,<sup>8</sup> there is a potential that this deficiency may be at the core of the apparent hyper-responsiveness of asthmatics to the inflammatory effects of SO<sub>2</sub>.

Key animal studies cited above have provided some suggestions regarding the importance of inflammation and its resolution after exposure to SO<sub>2</sub>. However, a common limiting characteristic of the prior SO<sub>2</sub> studies is that none has been attempted in a model deficient in IL-10, which presumably would be highly relevant to the case of asthma, as mentioned above. Previously published mouse studies utilizing the IL-10 double-knockout null mutant mouse (IL-10<sup>-/-</sup>)<sup>120</sup> have identified that a lack of IL-10 results in enhancement of AI,<sup>121,122</sup> which is associated with increased airway iNOS mRNA and iNOS protein,<sup>123</sup> as well as increased IL-4 levels (ie, a predominance of the Th-2 adaptive immune reaction).<sup>124–126</sup> However, none has been performed to determine whether a lack of IL-10 predisposes toward an increased AI and ROS response to SO<sub>2</sub>. This shortcoming in our understanding could be important, due to the fact that SO<sub>2</sub> inhalation has been implicated in the production of ROS within the lung, and the fact that asthmatics have increased airway levels of ROS and other inflammatory mediators.<sup>11,63</sup>

Some additional possible hints as to the potential importance of IL-10 in SO<sub>2</sub>-exacerbated allergic asthma include that select therapeutic interventions are known to increase endogenous levels of IL-10.<sup>127</sup> Regulatory T cells (Tregs; CD4<sup>+</sup>FoxP3<sup>+</sup> phenotype), including the inducible type 1 Treg (Tr1), can be utilized for immunotherapy against allergen sensitivity, as reviewed by Ogawa et al.<sup>127</sup> In that case, IL-10 production is upregulated via Tr1 cells, and immune tolerance is subsequently conferred.<sup>128–130</sup> Furthermore, the inducible form of heme oxygenase (HO-1), also known as heat-shock protein 32, is the enzyme that catalyzes the breakdown of heme, and is a probable candidate at the center of this phenomenon. For example, a characteristic of HO-1 is its ability to protect airway cells from ROS damage via anti-inflammatory and antioxidative processes involving increased secretion of IL-10 by Tregs and the overall promotion of Treg cell numbers.<sup>90,131–133</sup>



**Figure 1.** Schematic of  $\text{SO}_2$  cellular mechanisms. Effects of leukocyte recruitment in the airway following  $\text{SO}_2$  exposure, as well as effects of  $\text{SO}_2$  itself, are shown. ROS, as a direct product from  $\text{SO}_2$  exposure or via secretion from recruited leukocytes 1) promotes an oxidant status shift within the epithelial cell and 2) modulates gene and protein levels, which feed back into the oxidant status shift within the epithelial cell. X is the site of possible IL-10 inhibitory effects.

Therefore, it would appear essential to retain the functionality of Tregs in the airways. In that regard, specific allergen immunotherapy (SIT), which promotes allergen-specific Treg function, may be a therapeutic possibility to reverse the detrimental effects of  $\text{SO}_2$ -exacerbated allergic asthma, assuming that further research would support this possibility.

The consequences of IL-10 deficiency in asthma may also play a role in relation to asthmatic susceptibility to environmental toxicant/pollutant triggers, which may act as irritants promoting neurogenic inflammation, as outlined above. This process typically involves an early and late phase immune response, in which pro-inflammatory cytokines are released early (eg, IL-1 $\beta$ , IL-4, IL-5, IL-13, and TNF- $\alpha$ ), promoting eosinophilia,<sup>6,134,135</sup> followed by later release of IL-10, which blocks the early-phase-dependent inflammation and decreases eosinophilia.<sup>6,136</sup> Clearly, a deficiency in IL-10, as reported in asthmatics,<sup>8</sup> would likely hamper the resolution of inflammation.

In all, there appears to be suggestive evidence that asthmatics may be sensitive to  $\text{SO}_2$ , in part due to their inability to make significant amounts of IL-10, and that therapies targeted toward enhancing or restoring this capability might be beneficial. However, our current state of knowledge of this relationship is exceedingly minimal and requires further research.

## Conclusion

$\text{SO}_2$  is a recognized environmental toxicant that can act to promote airway responses in a concentration-dependent manner, possibly through its ability to induce local oxidative stress. Asthmatics have been shown to have a greater sensitivity

to  $\text{SO}_2$  than non-asthmatics, but the exact mechanisms are yet to be fully understood. Of relevance, the ROS/RNS production within the lung in response to  $\text{SO}_2$  exposure can be modified with antioxidant administration, providing insight into the putative mechanisms of  $\text{SO}_2$  effects and potential therapeutic applications in the setting of asthma. Furthermore, the airway inflammation resulting from the oxidative stress associated with  $\text{SO}_2$  exposure may be of greater magnitude in asthmatics, which may, in turn, be more difficult to resolve, as compared to non-asthmatics. Consideration of these possibilities suggests that enhanced  $\text{SO}_2$  effects in asthmatics could be potentially due to their inability to produce necessary amounts of IL-10 to resolve the inflammation resulting from  $\text{SO}_2$ -induced oxidative stress. Animal studies of  $\text{SO}_2$  in specifically targeted systems, such as IL-10 knockout mice and *in vitro* cellular small interfering (si)RNA knockdowns, may provide information necessary to better resolve this prospective link and provide additional therapeutic targets to protect asthmatics from potential pathology associated with the inhalation of  $\text{SO}_2$ .

## Acknowledgments

The authors would like to thank Dr. Lance M. Hallberg for expert review of this article, and Dr. William J. Calhoun, Dr. Rolf König, and Dr. Randall M. Goldblum for their concept support.

## Author Contributions

Conceived and designed the manuscript: ALR, BTA. Wrote the first draft of the manuscript: ALR, BTA. Contributed



to the writing of the manuscript: ALR, EGB, BTA. Jointly developed the structure and arguments for the paper: ALR, EGB, BTA. Made critical revisions and approved final version: ALR, EGB, BTA. All authors reviewed and approved of the final manuscript.

## REFERENCES

1. WHO. *Global Surveillance, Prevention and Control of Chronic Respiratory Diseases*. Geneva, Switzerland: WHO Press; 2007:15–6.
2. Rusconi F, Catelan D, Accetta G, et al. Asthma symptoms, lung function, and markers of oxidative stress and inflammation in children exposed to oil refinery pollution. *J Asthma*. 2011;48(1):84–90. doi: 10.3109/02770903.2010.538106.
3. Smargiassi A, Goldberg MS, Wheeler AJ, et al. Associations between personal exposure to air pollutants and lung function tests and cardiovascular indices among children with asthma living near an industrial complex and petroleum refineries. *Environ Res*. 2014;132:38–45. doi: 10.1016/j.envres.2014.03.030.
4. Yang C, Wang J, Chan C, Hwang J, Chen P. Respiratory symptoms of primary school children living in a petrochemical polluted area in Taiwan. *Pediatr Pulmonol*. 1998;25(5):299–303.
5. Bloemen K, Verstraelen S, Van Den Heuvel R, Witters H, Nelissen I, Schoeters G. The allergic cascade: review of the most important molecules in the asthmatic lung. *Immunol Lett*. 2007;113(1):6–18. doi: 10.1016/j.iml.2007.07.010.
6. Duramad P, Tager IB, Holland NT. Cytokines and other immunological biomarkers in children's environmental health studies. *Toxicol Lett*. 2007;172(1–2):48–59. doi: 10.1016/j.toxlet.2007.05.017.
7. Pandya RJ, Solomon G, Kinner A, Balmes JR. Diesel exhaust and asthma: hypotheses and molecular mechanisms of action. *Environ Health Perspect*. 2002;110(suppl 1):103–12.
8. Borish L, Aarons A, Rumblyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. *J Allergy Clin Immunol*. 1996;97(6):1288–96.
9. Calhoun W, Hinton K, Brick J, Sharma A, Rosen W. Spontaneous and stimulated IL-10 release by alveolar macrophages (AM) but not blood monocytes (BM) is reduced in allergic asthmatics (AA). *Am J Respir Crit Care Med*. 1996;153:A881.
10. Boldogh I, Bacsi A, Choudhury BK, et al. ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation. *J Clin Invest*. 2005;115(8):2169–79. doi: 10.1172/JCI24422.during.
11. Liu L, Poon R, Chen L, et al. Acute effects of air pollution on pulmonary function, airway inflammation, and oxidative stress in asthmatic children. *Environ Health Perspect*. 2009;117(4):668–74. doi: 10.1289/ehp11813.
12. Trasande L, Thurston GD. The role of air pollution in asthma and other pediatric morbidities. *J Allergy Clin Immunol*. 2005;115(4):689–99. doi: 10.1016/j.jaci.2005.01.056.
13. White CW, Martin JG. Chlorine gas inhalation: human clinical evidence of toxicity and experience in animal models. *Proc Am Thorac Soc*. 2010;7(4):257–63. doi: 10.1513/pats.201001-008SM.
14. Thompson AM, Zanobetti A, Silverman F, et al. Baseline repeated measures from controlled human exposure studies: associations between ambient air pollution exposure and the systemic inflammatory biomarkers IL-6 and fibrinogen. *Environ Health Perspect*. 2010;118(1):120–4. doi: 10.1289/ehp.0900550.
15. De Santis V, Onufrio G. Health risks of SO<sub>2</sub> released from coal-fired plants: a model for general evaluations. *Environ Res*. 1986;41(1):130–8.
16. Janssen A, Ruitenber R, Buisman C. Industrial applications of new sulphur biotechnology. *Water Sci Technol*. 2001;44(8):85–90.
17. WHO. Sulfur dioxide. *Air Quality Guidelines*. 2nd ed. 2000. [http://www.euro.who.int/\\_data/assets/pdf\\_file/0020/123086/AQG2ndEd\\_7\\_4Sulfurdioxide.pdf](http://www.euro.who.int/_data/assets/pdf_file/0020/123086/AQG2ndEd_7_4Sulfurdioxide.pdf). Accessed June 23, 2013.
18. Deger L, Plante C, Jacques L, et al. Active and uncontrolled asthma among children exposed to air stack emissions of sulphur dioxide from petroleum refineries in Montreal, Quebec: a cross-sectional study. *Can Respir J*. 2012;19(2):97–102.
19. Jang A-S, Yeum C-H, Son M-H. Epidemiologic evidence of a relationship between airway hyperresponsiveness and exposure to polluted air. *Allergy*. 2003;58(7):585–8.
20. WHO. Global ambient air pollution concentrations and trends. *Air Quality Guidelines: Global Update 2005*. 2006. [http://www.euro.who.int/\\_data/assets/pdf\\_file/0005/78638/E90038.pdf](http://www.euro.who.int/_data/assets/pdf_file/0005/78638/E90038.pdf). Accessed June 23, 2013.
21. Nieminen P, Panychev D, Lyalyushkin S, et al. Environmental exposure as an independent risk factor of chronic bronchitis in northwest Russia. *Int J Circumpolar Health*. 2013;72:19742–8.
22. Pohanish RP. Sulfur dioxide. *HazMat Data for First Response, Transportation, Storage, and Security*. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc; 2004:1022.
23. Brown JA. Haz-Map®: information on hazardous chemicals and occupational diseases: sulfur dioxide. *US Natl Libr Med*. 2012. <http://hazmap.nlm.nih.gov/category-details?id=25&table=copypblagents>. Accessed July 11, 2012.
24. HSDDB. Sulfur dioxide. *Natl Libr Med*. 2012. <http://toxnet.nlm.nih.gov/cgi-bin/sis/search/?/temp/~oZm2dk:1>. Accessed January 23, 2013.
25. Lin S, Hwang S-A, Pantea C, Kielb C, Fitzgerald E. Childhood asthma hospitalizations and ambient air sulfur dioxide concentrations in Bronx County, New York. *Arch Environ Health*. 2004;59(5):266–75. doi: 10.3200/AEOH.59.5.266-275.
26. Peden DB. Mechanisms of pollution-induced airway disease: in vivo studies. *Allergy*. 1997;52(suppl 38):37–44.
27. Schwela D. Air pollution and health in urban areas. *Rev Environ Health*. 2000;15(1–2):13–42.
28. Sheppard D, Saisho A, Nadel JA, Boushey HA. Exercise increases sulfur dioxide-induced bronchoconstriction in asthmatic subjects. *Am Rev Respir Dis*. 1981;123:486–91.
29. Raulf-Heimsoth M, Hoffmeyer F, van Thriel C, Blaszkewicz M, Bünger J, Brüning T. Assessment of low dose effects of acute sulphur dioxide exposure on the airways using non-invasive methods. *Arch Toxicol*. 2010;84(2):121–7. doi: 10.1007/s00204-009-0480-5.
30. D'Amato G, Liccardi G, D'Amato M, Cazzola M. Respiratory allergic diseases induced by outdoor air pollution in urban areas. *Monaldi Arch Chest Dis*. 2002;57(3–4):161–3.
31. WHO. *Sulfur Oxides and Suspended Particulate Matter (EHC 8)*. 1979. <http://www.inchem.org/documents/ehc/ehc/ehc008.htm>. Accessed June 23, 2013.
32. Takahashi Y, Miyoshi T, Higashi M, Kamioka H, Kanai Y. Neutralization of calcite in mineral aerosols by acidic sulfur species collected in China and Japan Studied by ca K-edge X-ray absorption near-edge structure. *Environ Sci Technol*. 2009;43(17):6535–40. doi: 10.1021/es9010256.
33. Waller R, Brooks A, Cartwright J. An electron microscope study of particles in town air. *Air Water Pollut*. 1963;7:779–86.
34. Schlipkoter H, Bruch J. Behaviour of the lung as an organ of absorption and reaction when air-borne contaminants are inhaled. *Zentralbl Bakteriol Orig B*. 1976;162(1/2):1–17.
35. NRC. Kate Kelly editor. Sulfur dioxide. *Review of Submarine Escape Action Levels for Selected Chemicals*. Washington, DC: National Academy Press; 2002:248–81.
36. Calabrese E, Sacco C, Moore G, DiNardi S. Sulfite oxidase deficiency: a high risk factor in SO<sub>2</sub>, sulfite, and bisulfite toxicity? *Med Hypotheses*. 1981;7:133–45.
37. Gunnison AF, Sellakumar A, Currie D, Snyder EA. Distribution, metabolism and toxicity of inhaled sulfur dioxide and endogenously generated sulfite in the respiratory tract of normal and sulfite oxidase-deficient rats. *J Toxicol Environ Health*. 1987;21(1/2):141–62.
38. Gunnison AF, Palmes ED. S-sulfonates in human plasma following inhalation of sulfur dioxide. *Am Ind Hyg Assoc J*. 1974;35(5):288–91.
39. Gunnison AF, Palmes ED. Species variability in plasma S-sulfonate levels during and following sulfite administration. *Chem Biol Interact*. 1978;21:315–29.
40. Bechtold WE, Waide JJ, Sandström T, et al. Biological markers of exposure to SO<sub>2</sub>: S-sulfonates in nasal lavage. *J Expo Anal Environ Epidemiol*. 1993;3(4):371–82.
41. Acosta R, Granados J, Mourelle M, Perez-Alvarez V, Quezada E. Sulfite sensitivity: relationship between sulfite plasma levels and bronchospasm: case report. *Ann Allergy*. 1989;62(5):402–5.
42. Ameredes BT. Translating airway biomarker information into practice: from theoretical science to applied medicine. *Pulm Pharmacol Ther*. 2011;24(2):187–92. doi: 10.1016/j.pupt.2010.09.006.
43. Winterton DL, Kaufman J, Keener CV, et al. Genetic polymorphisms as biomarkers of sensitivity to inhaled sulfur dioxide in subjects with asthma. *Ann Allergy Asthma Immunol*. 2001;86(2):232–8. doi: 10.1016/S1081-1206(10)62697-X.
44. Kharitonov SA, Barnes PJ. Clinical aspects of exhaled nitric oxide. *Eur Respir J*. 2000;16:781–92.
45. Forbes LJ, Patel MD, Rudnicka AR, et al. Chronic exposure to outdoor air pollution and markers of systemic inflammation. *Epidemiology*. 2009;20(2):245–53. doi: 10.1097/EDE.0b013e318190ea3f.
46. Ghio AJ, Kim C, Devlin RB. Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers. *Am J Respir Crit Care Med*. 2000;162:981–8.
47. Hoffmann B, Moebus S, Dragano N, et al. Chronic residential exposure to particulate matter air pollution and systemic inflammatory markers. *Environ Health Perspect*. 2009;117(8):1302–8. doi: 10.1289/ehp.0800362.
48. Shima M. Air pollution and serum C-reactive protein concentration in children. *J Epidemiol*. 2007;17(5):169–76.
49. Li R, Meng Z. Effects of SO<sub>2</sub> derivatives on expressions of MUC5AC and IL-13 in human bronchial epithelial cells. *Arch Toxicol*. 2007;81(12):867–74. doi: 10.1007/s00204-007-0212-7.
50. Li R, Meng Z, Xie J. Effects of sulfur dioxide derivatives on four asthma-related gene expressions in human bronchial epithelial cells. *Toxicol Lett*. 2007;175(1–3):71–81. doi: 10.1016/j.toxlet.2007.09.011.



51. Pelletier M, Lavastre V, Girard D. Activation of human epithelial lung a549 cells by the pollutant sodium sulfite: enhancement of neutrophil adhesion. *Toxicol Sci.* 2002;69(1):210–6.
52. Yang Y-F, Hsu J-Y, Fu L-S, Weng Y-S, Chu J-J. Asthma drugs counter-regulate interleukin-8 release stimulated by sodium sulfite in an A549 cell line. *J Asthma.* 2008;46(3):238–43. doi: 10.1080/02770900802628508.
53. Nadel J. Role of epidermal growth factor receptor activation in regulating mucin synthesis. *Respir Res.* 2001;2(2):85–9.
54. Burgel P-R, Nadel J. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. *Thorax.* 2004;59(11):992–6. doi: 10.1136/thx.2003.018879.
55. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R. Inter-cellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. *Science.* 1990;247(4941):456–9.
56. Park GY, Christman JW. Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. *Am J Physiol Lung Cell Mol Physiol.* 2006;290(5):L797–805. doi: 10.1152/ajplung.00513.2005.
57. Lim YJ, Na HS, Yun YS, et al. Suppressive effects of ginsan on the development of allergic reaction in murine asthmatic model. *Int Arch Allergy Immunol.* 2009;150(1):32–42. doi: 10.1159/000210378.
58. Misawa M, Nakano E. Airway constriction by xanthine/xanthine oxidase in guinea pigs in vivo. *J Toxicol Environ Health.* 1993;39(2):193–205.
59. Park J-K, Kim Y-K, Lee S-R, Cho S-H, Min K-U, Kim Y-Y. Repeated exposure to low levels of sulfur dioxide (SO<sub>2</sub>) enhances the development of ovalbumin-induced asthmatic reactions in guinea pigs. *Ann Allergy Asthma Immunol.* 2001;86(1):62–7.
60. Li Y, Wang J, He HY, et al. Immunohistochemical demonstration of airway epithelial cell markers of guinea pig. *Tissue Cell.* 2011;43(5):283–90. doi: 10.1016/j.tice.2011.05.003.
61. Handley D, DeLeo J, Havill A. Induction by aerosol allergen of sustained and nonspecific IgE-mediated airway hyperreactivity in the guinea pig. *Agents Actions.* 1992;37(3–4):201–3.
62. Ramos-Ramírez P, Campos M, Martínez-Cordero E, Bazán-Perkins B, García-Zepeda E. Antigen-induced airway hyperresponsiveness in absence of broncho-obstruction in sensitized guinea pigs. *Exp Lung Res.* 2013;39(3):136–45.
63. Cai C, Xu J, Zhang M, et al. Prior SO<sub>2</sub> exposure promotes airway inflammation and subepithelial fibrosis following repeated ovalbumin challenge. *Clin Exp Allergy.* 2008;38(10):1680–7. doi: 10.1111/j.1365-2222.2008.03053.x.
64. Lin H-K, Tsai J-J, Wen M-C, Tsai M-C, Chen C-J, Fu L-S. Sodium sulfite aggravated allergic sensitization and airway inflammation in mite allergen sensitized BALB/c mice. *Hum Exp Toxicol.* 2011;30(10):1682–9. doi: 10.1177/0960327111398673.
65. Meng Z, Qin G, Zhang B, et al. Oxidative damage of sulfur dioxide inhalation on lungs and hearts of mice. *Environ Res.* 2003;93(3):285–92. doi: 10.1016/S0013-9351(03)00045-8.
66. Meng Z, Li R, Zhang X. Levels of sulfite in three organs from mice exposed to sulfur dioxide. *Inhal Toxicol.* 2005;17(6):309–13. doi: 10.1080/08958370590922634.
67. Meng Z, Liu Y, Wu D. Effect of sulfur dioxide inhalation on cytokine levels in lungs and serum of mice. *Inhal Toxicol.* 2005;17(6):303–7. doi: 10.1080/08958370590922625.
68. Beck-Speier I, Hinze H, Holzer H. Effect of sulfite on the energy metabolism of mammalian tissues in correlation to sulfite oxidase activity. *Biochim Biophys Acta.* 1985;841:81–9.
69. Cabré F, Marín C, Cascante M, Canela EI. Occurrence and comparison of sulfite oxidase activity in mammalian tissues. *Biochem Med Metab Biol.* 1990;43(2):159–62.
70. Maier KL, Wippermann U, Leuschel L, et al. Xenobiotic-metabolizing enzymes in the canine respiratory tract. *Inhal Toxicol.* 1999;11:19–35.
71. Gavett SH, Wills-Karp M. Elevated lung G protein levels and muscarinic receptor affinity in a mouse model of airway hyperreactivity. *Am J Physiol.* 1993;265(5 pt 1):L493–500.
72. Bai J, Meng Z. Effects of sulfur dioxide on apoptosis-related gene expressions in lungs from rats. *Regul Toxicol Pharmacol.* 2005;43(3):272–9. doi: 10.1016/j.yrtph.2005.09.002.
73. Li R, Meng Z, Xie J. Effects of sulfur dioxide on the expressions of MUC5AC and ICAM-1 in airway of asthmatic rats. *Regul Toxicol Pharmacol.* 2007;48(3):284–91. doi: 10.1016/j.yrtph.2007.04.009.
74. Li R, Meng Z, Xie J. Effects of sulfur dioxide on the expressions of EGF. *Arch Environ Contam Toxicol.* 2008;54(4):748–57. doi: 10.1007/s00244-007-9054-9.
75. Qin G, Meng Z. Effect of sulfur dioxide inhalation on CYP1A1 and CYP1A2 in rat liver and lung. *Toxicol Lett.* 2005;160(1):34–42. doi: 10.1016/j.toxlet.2005.06.002.
76. Xie J, Li R, Fan R, Meng Z. Effects of sulfur dioxide on expressions of p53, bax and bcl-2 in lungs of asthmatic rats. *Inhal Toxicol.* 2009;21(11):952–7. doi: 10.1080/08958370802629602.
77. Yun Y, Hou L, Sang N. SO<sub>2</sub> inhalation modulates the expression of pro-inflammatory and pro-apoptotic genes in rat heart and lung. *J Hazard Mater.* 2011;185(1):482–8. doi: 10.1016/j.jhazmat.2010.09.057.
78. Abdulmir AS, Hafidh RR, Abubakar F, Abbas KA. Changing survival, memory cell compartment, and T-helper balance of lymphocytes between severe and mild asthma. *BMC Immunol.* 2008;9:73–82. doi: 10.1186/1471-2172-9-73.
79. Suzuki S, Matsukura S, Takeuchi H, et al. Increase in reactive oxygen metabolite level in acute exacerbations of asthma. *Int Arch Allergy Immunol.* 2008;146(suppl 1):67–72. doi: 10.1159/000126064.
80. Beck-Speier I, Liese JG, Belohradsky BH, Godleski JJ. Sulfite stimulates NADPH oxidase of human neutrophils to produce active oxygen radicals via protein kinase C and Ca<sup>2+</sup>/calmodulin pathways. *Free Radic Biol Med.* 1993;14:661–8.
81. Kienast K, Müller-Quernheim J, Knorst M, Lubjuhn S, Ferlinz R. *In vitro* study of human alveolar macrophage and peripheral blood mononuclear cell reactive oxygen-intermediates release induced by sulfur dioxide at different concentrations. *Lung.* 1994;172(6):335–45.
82. Labbé P, Pelletier M, Omara FO, Girard D. Functional responses of human neutrophils to sodium sulfite (Na<sub>2</sub>SO<sub>3</sub>) in vitro. *Hum Exp Toxicol.* 1998;17(11):600–5.
83. Collaco CR, Hochman DJ, Goldblum RM, Brooks EG. Effect of sodium sulfite on mast cell degranulation and oxidant stress. *Ann Allergy Asthma Immunol.* 2006;96(4):550–6. doi: 10.1016/S1081-1206(10)63549-1.
84. Yang I, Fong K, Zimmerman P, Holgate S, Holloway J. Genetic susceptibility to the respiratory effects of air pollution. *Thorax.* 2008;63:555–63. doi: 10.1136/thx.2007.079426.
85. Ahmed MN, Codipilly C, Hogg N, Auten RL. The protective effect of overexpression of extracellular superoxide dismutase on nitric oxide bioavailability in the lung after exposure to hyperoxia stress. *Exp Lung Res.* 2011;37:10–7.
86. Ghosh S, Erzurum SC. Nitric oxide metabolism in asthma pathophysiology. *Biochim Biophys Acta.* 2011;1810(11):1008–16. doi: 10.1016/j.bbagen.2011.06.009.
87. Zhao H, Xu X, Na J, et al. Protective effects of salicylic acid and vitamin C on sulfur dioxide-induced lipid peroxidation in mice. *Inhal Toxicol.* 2008;20(9):865–71. doi: 10.1080/08958370701861512.
88. Fattman C, Schaefer L, Oury T. Extracellular superoxide dismutase in biology and medicine. *Free Radic Biol Med.* 2003;35(3):236–56. doi: 10.1016/S0891-5849(03)00275-2.
89. Tan RJ, Fattman CL, Watkins SC, Oury TD. Redistribution of pulmonary EC-SOD after exposure to asbestos. *J Appl Physiol.* 2004;97(5):2006–13. doi: 10.1152/jappphysiol.00480.2004.
90. Xia ZW, Xu LQ, Zhong WW, et al. Heme oxygenase-1 attenuates ovalbumin-induced airway inflammation by up-regulation of foxp3 T-regulatory cells, interleukin-10, and membrane-bound transforming growth factor-1. *Am J Pathol.* 2007;171(6):1904–14. doi: 10.2353/ajpath.2007.070096.
91. Brehm JM, Schuemann B, Fuhlbrigge AL, et al; Childhood Asthma Management Program Research Group. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. *J Allergy Clin Immunol.* 2010;126(1):52–8. doi: 10.1016/j.jaci.2010.03.043.
92. Cohen HA, Neuman I, Nahum H. Blocking effect of vitamin C in exercise-induced asthma. *Arch Pediatr Adolesc Med.* 1997;151:367–70.
93. Fogarty A, Lewis SA, Scrivener SL, et al. Corticosteroid sparing effects of vitamin C and magnesium in asthma: a randomised trial. *Respir Med.* 2006;100(1):174–9. doi: 10.1016/j.rmed.2005.03.038.
94. Hollams EM, Hart PH, Holt BJ, et al. Vitamin D and atopy and asthma phenotypes in children: a longitudinal cohort study. *Eur Respir J.* 2011;38(6):1320–7. doi: 10.1183/09031936.00029011.
95. Redlich CA, Grauer JN, Van Bennekum AM, Clever SL, Ponn RB, Blaner WS. Characterization of carotenoid, vitamin A, and alpha-tocopherol levels in human lung tissue and pulmonary macrophages. *Am J Respir Crit Care Med.* 1996;154(5):1436–43. doi: 10.1164/ajrccm.154.5.8912761.
96. Schachter EN, Schlesinger A. The attenuation of exercise-induced bronchospasm by ascorbic acid. *Ann Allergy.* 1982;49(3):146–51.
97. Tecklenburg SL, Mickleborough TD, Fly AD, Bai Y, Stager JM. Ascorbic acid supplementation attenuates exercise-induced bronchoconstriction in patients with asthma. *Respir Med.* 2007;101(8):1770–8. doi: 10.1016/j.rmed.2007.02.014.
98. Trenga CA, Koenig JQ, Williams PV. Sulphur dioxide sensitivity and plasma antioxidants in adult subjects with asthma. *Occup Environ Med.* 1999;56(8):544–7.
99. Trenga CA, Koenig JQ, Williams PV. Dietary antioxidants and ozone-induced bronchial hyperresponsiveness in adults with asthma. *Arch Environ Health.* 2001;56(3):242–9.
100. Wu AC, Tantisira K, Li L, Fuhlbrigge AL, Weiss ST, Litonjua A. Effect of vitamin D and inhaled corticosteroid treatment on lung function in children. *Am J Respir Crit Care Med.* 2012;186(6):508–13. doi: 10.1164/rccm.201202-0351OC.
101. Castro M, King TS, Kunselman SJ, et al. National Heart, Lung, and Blood Institute's AsthmaNet. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *JAMA.* 2014;311(20):2083–91. doi: 10.1001/jama.2014.5052.
102. Meggs WJ. Neurogenic inflammation and sensitivity to environmental chemicals. *Environ Health Perspect.* 1993;101(3):234–8.
103. Aoki H, Mogi C, Okajima F. Ionotropic and metabotropic proton-sensing receptors involved in airway inflammation in allergic asthma. *Mediators Inflamm.* 2014;2014:712962. doi: 10.1155/2014/712962.



104. McLeod RL, Jia Y, McHugh NA, et al. Sulfur-dioxide exposure increases TRPV1-mediated responses in nodose ganglia cells and augments cough in guinea pigs. *Pulm Pharmacol Ther.* 2007;20(6):750–7. doi: 10.1016/j.pupt.2006.09.003.
105. Bannenberg G, Atzori L, Xue J, et al. Sulfur dioxide and sodium metabisulfite induce bronchoconstriction in the isolated perfused and ventilated guinea pig lung via stimulation of capsaicin-sensitive sensory nerves. *Respiration.* 1994; 61(3):130–7.
106. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. *Immunol Rev.* 2011;242(1):220–32. doi: 10.1111/j.1600-065X.2011.01032.x.
107. Pawelek-Krombolz D, Konecki J, Kaminski M, Helewski K. Effect of sulfuric acid vapors on the respiratory system. *Med Pr.* 1985;36(4):229–35.
108. Hunt JF, Fang K, Malik R, et al. Endogenous airway acidification. Implications for asthma pathophysiology. *Am J Respir Crit Care Med.* 2000;161(3 pt 1):694–9.
109. Ricciardolo FL, Gaston B, Hunt J. Acid stress in the pathology of asthma. *J Allergy Clin Immunol.* 2004;113(4):610–9. doi: 10.1016/j.jaci.2003.12.034.
110. Wood PR, Hill VL, Burks ML, et al. Mycoplasma pneumoniae in children with acute and refractory asthma. *Ann Allergy Asthma Immunol.* 2013;110(5):328–34. doi: 10.1016/j.anaai.2013.01.022.
111. Barnes PJ. Neurogenic inflammation in the airways. *Respir Physiol.* 2001;125(1–2):145–54.
112. Fujimaki H, Kurokawa Y, Kunugita N, Kikuchi M, Sato F, Arashidani K. Differential immunogenic and neurogenic inflammatory responses in an allergic mouse model exposed to low levels of formaldehyde. *Toxicology.* 2004;197(1):1–13. doi: 10.1016/j.tox.2003.11.015.
113. Lin H, Qi H, Fang L, Li S, Li Z, Xie B. To explore the mechanisms of neurogenic inflammation and airway hyperresponsiveness of rat by inhaled sulfur. *Chinese J Appl Physiol.* 2009;25(1):113–6.
114. US EPA. *Formaldehyde: Hazard Summary.* 2003. <http://www.epa.gov/ttn/atw/hlthef/formalde.html>. Accessed June 27, 2014.
115. WHO. *LARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 88 Formaldehyde, 2-Butoxyethanol and 1-Tert-Butoxypropan-2-OL.* 2006:1–9. <http://monographs.iarc.fr/ENG/Monographs/vol88/volume88.pdf>.
116. WHO. *International Program on Chemical Safety, Environmental Health Criteria 89: Formaldehyde.* 1999. <http://www.inchem.org/documents/ehc/ehc/ehc89.htm>. Accessed June 27, 2014.
117. Dao Nguyen X, Robinson DS. Fluticasone propionate increases CD4+CD25+ T regulatory cell suppression of allergen-stimulated CD4+CD25+ T cells by an IL-10-dependent mechanism. *J Allergy Clin Immunol.* 2004;114(2):296–301. doi: 10.1016/j.jaci.2004.04.048.
118. Peek EJ, Richards DF, Faith A, et al. Interleukin-10-secreting “regulatory” T cells induced by glucocorticoids and beta-2-agonists. *Am J Respir Cell Mol Biol.* 2005;33(1):105–11. doi: 10.1165/rcmb.2005-0100OC.
119. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. *Clin Exp Allergy.* 2002;32(2):264–9.
120. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell.* 1993;75(2):263–74.
121. Tournoy KG, Kips JC, Pauwels RA. Endogenous interleukin-10 suppresses allergen-induced airway inflammation and nonspecific airway responsiveness. *Clin Exp Allergy.* 2000;30(6):775–83.
122. Vissers JL, van Esch BC, Jeurink PV, Hofman GA, van Oosterhout AJ. Stimulation of allergen-loaded macrophages by TLR9-ligand potentiates IL-10-mediated suppression of allergic airway inflammation in mice. *Respir Res.* 2004;5:21–28. doi: 10.1186/1465-9921-5-21.
123. Ameredes BT, Zamora R, Gibson KF, et al. Increased nitric oxide production by airway cells of sensitized and challenged IL-10 knockout mice. *J Leukoc Biol.* 2001;70(5):730–6.
124. Mäkelä MJ, Kanehiro A, Borish L, et al. IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. *Proc Natl Acad Sci U S A.* 2000;97(11):6007–12. doi: 10.1073/pnas.100118997.
125. Justice JP, Shibata Y, Sur S, Mustafa J, Fan M, Van Scott MR. IL-10 gene knockout attenuates allergen-induced airway hyperresponsiveness in C57BL/6 mice. *Am J Physiol Lung Cell Mol Physiol.* 2001;280:L363–8.
126. Ameredes BT, Zamora R, Sethi JM, et al. Alterations in nitric oxide and cytokine production with airway inflammation in the absence of IL-10. *J Immunol.* 2005;175(2):1206–13.
127. Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. *Curr Mol Med.* 2008;8(5):437–45.
128. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. *J Allergy Clin Immunol.* 2004;113(6):1025–34. doi: 10.1016/j.jaci.2004.03.024.
129. Wei W, Liu Y, Wang Y, et al. Induction of CD4+CD25+Foxp3+IL-10+ T cells in HDM-allergic asthmatic children with or without SIT. *Int Arch Allergy Immunol.* 2010;153(1):19–26.
130. Lou W, Wang C, Wang Y, Han D, Zhang L. Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type 1 T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. *Pediatr Allergy Immunol.* 2012;23(2):140–9. doi: 10.1111/j.1399-3038.2011.01249.x.
131. Almolki A, Taillé C, Martin GF, et al. Heme oxygenase attenuates allergen-induced airway inflammation and hyperreactivity in guinea pigs. *Am J Physiol Lung Cell Mol Physiol.* 2004;287(1):L26–34. doi: 10.1152/ajplung.00237.2003.
132. Rytter SW, Choi AM. Heme oxygenase-1: redox regulation of a stress protein in lung and cell culture models. *Antioxid Redox Signal.* 2005;7(1–2):80–91. doi: 10.1089/ars.2005.7.80.
133. Xia ZW, Zhong WW, Xu LQ, et al. Heme oxygenase-1-mediated CD4+CD25high regulatory T cells suppress allergic airway inflammation. *J Immunol.* 2006;177(9):5936–45.
134. Kuo ML, Huang JL, Yeh KW, Li PS, Hsieh KH. Evaluation of Th1/Th2 ratio and cytokine production profile during acute exacerbation and convalescence in asthmatic children. *Ann Allergy Asthma Immunol.* 2001;86(3):272–6. doi: 10.1016/S1081-1206(10)63297-8.
135. Borges VM, Vandivier RW, McPhillips KA, et al. TNFalpha inhibits apoptotic cell clearance in the lung, exacerbating acute inflammation. *Am J Physiol Lung Cell Mol Physiol.* 2009;297(4):L586–95. doi: 10.1152/ajplung.90569.2008.
136. Sierra-Filardi E, Vega MA, Sánchez-Mateos P, Corbí AL, Puig-Kröger A. Heme oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. *Immunobiology.* 2010;215(9–10):788–95. doi: 10.1016/j.imbio.2010.05.020.
137. US EPA. *Sulfur Dioxide (SO2) Primary Standards – Table of Historical SO2 NAAQS.* 2013. [http://www.epa.gov/ttn/naaqs/standards/so2/s\\_so2\\_history.html](http://www.epa.gov/ttn/naaqs/standards/so2/s_so2_history.html). Accessed June 24, 2013.